Alamar Biosciences Inc
Company Profile
Business description
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Contact
47071 Bayside Parkway
FremontCA94538
USAT: +1 510 626-9888
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
ASX energy share remains cheap despite strong outlook
stocks
Moated AI-proof tech play hiding in the ASX 100
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,990.80 | 20.60 | 0.23% |
| CAC 40 | 8,189.86 | 32.04 | 0.39% |
| DAX 40 | 24,277.95 | 148.97 | 0.62% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,394.31 | 15.23 | 0.15% |
| HKSE | 25,925.65 | 52.42 | -0.20% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 60,537.36 | 821.18 | 1.38% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 56.68 | 0.80% |
| S&P/ASX 200 | 8,766.40 | 17.20 | 0.20% |
| SSE Composite Index | 4,086.34 | 6.44 | 0.16% |